Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

APRI $1.70 0.3500 +25.93%
CTIX $1.99 0.2250 +12.78%
GALT $2.21 0.2500 +12.76%
OGXI $2.91 0.2300 +8.58%
CERU $4.03 0.2500 +6.61%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PARD $0.08 -0.1100 -57.89%
FATE $6.53 -0.6800 -9.43%
SRNE $12.68 -0.9700 -7.11%
GERN $3.03 -0.2000 -6.19%
UTHR $150.62 -9.8600 -6.14%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

(StreetInsider) Aug 24, 2015 - Medivation, Inc. and BioMarin Pharmaceutical Inc. announced today that they have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
read article 

AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

(AstraZeneca) Aug 24, 2015 - Collaboration to focus on cancer immunotherapy combination of Peregrine’s ps-targeting bavituximab and AstraZeneca’s PD-L1 Inhibitor MEDI4736.
read corporate press release 

Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma

(Benzinga) Aug 24, 2015 - Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted the company's investigational new drug (IND) application for tazemetostat for the treatment of adults and pediatric patients with INI1-negative tumors or synovial sarcoma.
read article 

Orbus Gets $32.5M To Repurpose Hirsutism Drug For Brain Cancer

(MedCity News) Aug 21, 2015 - An already-approved drug used to treat excess facial hair and sleeping sickness may have an important new purpose: Treating brain cancer.
read article (free registration required) 

MTG Biotherapeutics Announces that MTG-201 was Granted Orphan Drug Designation by the US FDA for the Treatment of Malignant Mesothelioma

(TheStreet) Aug 21, 2015 - MTG Biotherapeutics today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.
read article 

ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial

(ImmunoCellular) Aug 21, 2015 - ImmunoCellular Therapeutics, Ltd. today issued the following letter to shareholders.
read corporate press release 

Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction of Cardiac Toxicity Monitoring for NeuVax(TM) PRESENT Trial

(TheStreet) Aug 24, 2015 - Galena Biopharma, Inc. today announced that the Independent Data Monitoring Committee (IDMC) has recommended to the Company that it can reduce the cardiac toxicity monitoring for patients in its NeuVax™ (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTreatment) clinical trial.
read article 

FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy

(Yahoo! Finance) Aug 24, 2015 - Exelixis, Inc. today announced the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib, Exelixis’ lead compound, as a potential treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.
read article 

FDA Extends Use Of Promacta In Young Children With Rare Blood Disorder

( Aug 24, 2015 - The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP).
read press release 

Helix BioPharma Corp. Announces Upcoming Presentation of L-DOS47 at World Conference on Lung Cancer

(MarketWired) Aug 23, 2015 - Helix BioPharma Corp. today announced that an abstract for its lead lung cancer candidate L-DOS47 has been selected for oral presentation at the 16th World Conference on Lung Cancer (WCLC) held in Denver, Colorado, September 6-9, 2015.
read article 

Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer

(MarketWatch) Aug 23, 2015 - Five Prime Therapeutics, Inc. today announced that initial data from GlaxoSmithKline (GSK)'s ongoing Phase 1b trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non small cell lung cancer (sqNSCLC) and mesothelioma will be featured in an oral presentation by study investigators during the upcoming World Conference on Lung Cancer 2015 in Denver (September 6-9, 2015).
read article 

Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as Late-Breaker Presentation in Presidential Session at European Cancer Congress 2015

(MarketWatch) Aug 24, 2015 - Exelixis, Inc. today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of three presentations at the European Cancer Congress (ECC) 2015, which will be held September 25-29, 2015, in Vienna, Austria.
read article 

Blood Vessel Cells Help Tumours Evade The Immune System

(Karolinska Institutet [Stockholm, Sweden]) Aug 24, 2015 - A study by researchers at Karolinska Institutet is the first to suggest that cells in the tumour blood vessels contribute to a local environment that protects the cancer cells from tumour-killing immune cells. The results can contribute to the development of better immune-based cancer therapies.
read article 

Children’s Hospitals Shift from CT Scans for Common Childhood Health Problems

(Cincinnati Children’s) Aug 24, 2015 - A study published online Aug. 24 by the journal Pediatrics finds a significant decrease in the use of computed tomography (CT) scans at children’s hospitals for 10 common childhood diagnoses including seizure, concussion, appendectomy and upper respiratory tract infection.
read press release 

Clinical Trials OK for High-Grade Glioma Patients

(MedPage Today) Aug 21, 2015 - Patients with high-grade gliomas (HGG) who meet standard eligibility criteria may be good candidates for solid tumor phase I studies with single-agent molecular or cytotoxic drugs, a multi-institutional pooled analysis of Phase I oncology studies has shown.
read article (free registration required) 

Advanced Basal Cell Cancer: Think Older, Sicker

(MedPage Today) Aug 21, 2015 - Locally advanced and metastatic basal cell carcinoma (BCC) remain uncommon but tend to cluster in older, sicker patients, an analysis of a large insurance claims database showed.
read article (free registration required) 

Second Cancers Are on the Rise; 1 in 5 US Cases Is a Repeat

(ABC News/Associated Press) Aug 24, 2015 - Second cancers are on the rise. Nearly 1 in 5 new cases in the U.S. now involves someone who has had the disease before.
read article 

New Tool Will Compare Costs Versus Benefits Of Cancer Treatments

(Reuters) Aug 21, 2015 - As options for cancer patients become increasingly complicated, and expensive, the most influential source for U.S. oncology treatment guidelines will for the first time offer a tool to assess the costs versus benefits of available therapies.
read article 

Heart Drug Linked to Extra Years for Cancer Patients

(Wall Street Journal) Aug 24, 2015 - A type of beta blocker is tied to more than four-year increase in survival for women with ovarian cancer, study finds.
read article (paid subscription required) 

Northwest Bio Suspends Patient Screening In Brain Cancer Trial

(Reuters) Aug 21, 2015 - The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug.
read article 

Maintaining Rigorous Drug Development Standards In Personalized Cancer Treatment

(Harvard T.H. Chan School of Public Health) Aug 20, 2015 - New advances in genomic testing have the potential to radically change the way cancer drugs are developed and prescribed, offering personalized therapy with treatment tailored to the patient’s tumor genome.
read article 

Jimmy Carter May Benefit From Revolution in Cancer Immune Drugs

(Bloomberg) Aug 20, 2015 - Melanoma that metastasizes to the brain used to be among cancer’s most dismal and deadly diagnoses. New treatments, including precise radiation and drugs that stimulate the immune system, are improving patients’ chances and may directly benefit former President Jimmy Carter.
read article 

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

(TheStreet) Aug 21, 2015 - Biotech columnist Adam Feuerstein answers readers' questions about health care.
read article 

A Racial Gap In Attitudes Toward Hospice Care

(New York Times) Aug 21, 2015 - Twice already Narseary and Vernal Harris have watched a son die. The first time — Paul, at age 26 — was agonizing and frenzied, his body tethered to a machine meant to keep him alive as his incurable sickle cell disease progressed.
read article 

FDA To 'Low-T' Drug Makers: Prove It

(MedPage Today) Aug 20, 2015 - The FDA is requiring companies that make testosterone products to conduct a large clinical trial to determine the true risks and benefits of using the hormone, the agency said.
read article (free registration required)